The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Remicade (Infliximab) Monoclonal Antibody Market Research Report 2025

Global Remicade (Infliximab) Monoclonal Antibody Market Research Report 2025

Publishing Date : Mar, 2025

License Type :

Report Code : 1739065

No of Pages : 66

Ask Your Query

Report Description
Table of Content

Synopsis
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.

Global Remicade (Infliximab) Monoclonal Antibody market is projected to reach US$ 3855 million in 2029, increasing from US$ 2550 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Remicade (Infliximab) Monoclonal Antibody market research.

The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Remicade (Infliximab) Monoclonal Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

J & J
Pfizer
Organon
Amgen

Segment by Type

Brand
Biosimilar

Segment by Application

Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other

Consumption by Region

North America (United States, Canada)
Europe (Germany, France, U.K., Italy, Russia)
Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
Latin America (Mexico, Brazil, Argentina)
Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Remicade (Infliximab) Monoclonal Antibody report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Remicade (Infliximab) Monoclonal Antibody Market Overview
1.1 Product Overview and Scope of Remicade (Infliximab) Monoclonal Antibody
1.2 Remicade (Infliximab) Monoclonal Antibody Segment by Type
1.2.1 Global Remicade (Infliximab) Monoclonal Antibody Market Value Comparison by Type (2023-2029)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Remicade (Infliximab) Monoclonal Antibody Segment by Application
1.3.1 Global Remicade (Infliximab) Monoclonal Antibody Market Value by Application: (2023-2029)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Remicade (Infliximab) Monoclonal Antibody Market Size Estimates and Forecasts
1.4.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue 2018-2029
1.4.2 Global Remicade (Infliximab) Monoclonal Antibody Sales 2018-2029
1.4.3 Global Remicade (Infliximab) Monoclonal Antibody Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Remicade (Infliximab) Monoclonal Antibody Market Competition by Manufacturers
2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Manufacturers (2018-2023)
2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturers (2018-2023)
2.4 Global Remicade (Infliximab) Monoclonal Antibody Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody, Product Type & Application
2.7 Remicade (Infliximab) Monoclonal Antibody Market Competitive Situation and Trends
2.7.1 Remicade (Infliximab) Monoclonal Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Remicade (Infliximab) Monoclonal Antibody Players Market Share by Revenue
2.7.3 Global Remicade (Infliximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Remicade (Infliximab) Monoclonal Antibody Retrospective Market Scenario by Region
3.1 Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Remicade (Infliximab) Monoclonal Antibody Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2018-2029
3.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2018-2023
3.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Region: 2024-2029
3.3 Global Remicade (Infliximab) Monoclonal Antibody Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2018-2029
3.3.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2018-2023
3.3.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Region: 2024-2029
3.4 North America Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.4.1 North America Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2029)
3.4.3 North America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.5.1 Europe Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2029)
3.5.3 Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2029)
3.6.3 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.7.1 Latin America Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2029)
3.7.3 Latin America Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2029)
3.8.3 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2018-2029)
4.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2018-2023)
4.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Type (2024-2029)
4.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2018-2029)
4.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2018-2029)
4.2.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2018-2023)
4.2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Type (2024-2029)
4.2.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Type (2018-2029)
4.3 Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2018-2029)
5 Segment by Application
5.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2018-2029)
5.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2018-2023)
5.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales by Application (2024-2029)
5.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Application (2018-2029)
5.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2018-2029)
5.2.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2018-2023)
5.2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Application (2024-2029)
5.2.3 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Application (2018-2029)
5.3 Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2018-2029)
6 Key Companies Profiled
6.1 J & J
6.1.1 J & J Corporation Information
6.1.2 J & J Description and Business Overview
6.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.1.5 J & J Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon
6.3.1 Organon Corporation Information
6.3.2 Organon Description and Business Overview
6.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.3.5 Organon Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Remicade (Infliximab) Monoclonal Antibody Industry Chain Analysis
7.2 Remicade (Infliximab) Monoclonal Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Remicade (Infliximab) Monoclonal Antibody Production Mode & Process
7.4 Remicade (Infliximab) Monoclonal Antibody Sales and Marketing
7.4.1 Remicade (Infliximab) Monoclonal Antibody Sales Channels
7.4.2 Remicade (Infliximab) Monoclonal Antibody Distributors
7.5 Remicade (Infliximab) Monoclonal Antibody Customers
8 Remicade (Infliximab) Monoclonal Antibody Market Dynamics
8.1 Remicade (Infliximab) Monoclonal Antibody Industry Trends
8.2 Remicade (Infliximab) Monoclonal Antibody Market Drivers
8.3 Remicade (Infliximab) Monoclonal Antibody Market Challenges
8.4 Remicade (Infliximab) Monoclonal Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Skin Analysis Instrument Market Research Report, 2020-2031

Global Netilmicin Market Research Report 2025

Global CD25 (IL2R alpha) ELISA Kit Market Research Report 2025

Global Algae Oil DHA Gummies Market Research Report 2025

Global Life Sciences Microscopy Devices Market Research Report 2025

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}